Private Advisor Group LLC Cuts Stock Holdings in Novo Nordisk A/S $NVO

Private Advisor Group LLC reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 20.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,000 shares of the company’s stock after selling 17,770 shares during the period. Private Advisor Group LLC’s holdings in Novo Nordisk A/S were worth $2,573,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Revolve Wealth Partners LLC raised its position in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after buying an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC increased its stake in shares of Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after buying an additional 1,587 shares during the period. Invesco Ltd. lifted its stake in Novo Nordisk A/S by 26.3% in the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after acquiring an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL purchased a new position in Novo Nordisk A/S in the second quarter worth approximately $314,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk launched Awiqli, the world’s first once-weekly basal insulin, in India, expanding its diabetes portfolio in one of the world’s largest and fastest-growing diabetes markets. The rollout could provide a new growth avenue and reinforces the company’s leadership in diabetes care. Article Title
• Positive Sentiment: Another report highlighted the India insulin launch as a meaningful innovation for diabetes treatment, which may improve investor sentiment around Novo Nordisk’s long-term pipeline and international expansion. Article Title
• Positive Sentiment: A separate piece said Novo Nordisk remains undervalued despite the Wegovy label update, suggesting the market may still be pricing in a cautious outlook even as the company preserves a strong long-term obesity-drug story. Article Title
• Neutral Sentiment: Novo Nordisk also expanded its collaboration with MAHE’s GBS in pharmacometrics, a strategic but likely modest near-term market-moving development. Article Title
• Neutral Sentiment: The company signed a pact with Vivani for a long-lasting semaglutide implant, which adds to its pipeline optionality but is still early-stage and not an immediate earnings driver. Article Title
• Negative Sentiment: Recent prescription-tracker data pointed to a slowdown in demand for the oral Wegovy pill in the U.S., raising concerns that growth in Novo Nordisk’s GLP-1 franchise may be cooling after a strong run. Article Title
• Negative Sentiment: The stock also came under pressure in recent trading after falling more than the broader market, reflecting investor caution around near-term GLP-1 growth trends and valuation. Article Title

Novo Nordisk A/S Stock Up 0.1%

NVO stock opened at $48.93 on Friday. The stock has a market cap of $218.48 billion, a P/E ratio of 11.49, a PEG ratio of 4.46 and a beta of 0.77. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $71.79. The company’s 50 day moving average is $45.39 and its two-hundred day moving average is $45.85.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Research analysts expect that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent analyst reports. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Wolfe Research started coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating on the stock. Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price target on the stock. Finally, Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Five investment analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.